Shattuck Labs(NASDAQ) STTK

Shattuck helps people suffering from painful immune diseases like Crohn's. It makes medicines that stop the body from attacking itself. These treatments aim to help patients live better, healthier lives.

Designing New Ways to Fight Disease

• SL-325: Targeted protein treatment designed to block the DR3 receptor, a cellular switch that triggers chronic inflammation.
• SL-425: Specialized version of the lead drug candidate engineered to remain active in the body for longer periods.
• Bispecific Antibodies: Experimental treatments designed to block two different disease-causing pathways at the same time.

Recent Milestones and Future Plans

• Finished a safety study in primates to support human testing for the lead drug program.
• Started a Phase 1 early-stage clinical trial to evaluate the safety of SL-325 in healthy human volunteers.
• Maintained a manufacturing partnership with Kemwell Biopharma Private Limited to produce drug materials for clinical research.
• Planned the start of a Phase 2 mid-stage trial for Crohn's disease patients in the third quarter of 2026.

Specialized Science for Better Results

Shattuck focuses on blocking immune receptors directly to prevent the body from rejecting the medicine. This targeted approach may lead to more durable results for patients with chronic inflammatory conditions.

Tracking the Financial Progress

• Net loss reached $12.6 million in Q4 2025, an improvement of 32.6% from the previous year.
• Free cash flow reached -$8.5 million in Q4 2025, narrowing 51.1% from the same period in 2024.
• Market capitalization grew to $378.8 million in Q4 2025, up 515.8% year-over-year.
• Revenue fell to $0 in Q4 2025, representing a 100% decrease from $714,000 two years earlier.

Evolution of the Business

Shattuck has transitioned from early research into active human testing for its unique immune system treatments. Its focus on long-lasting, targeted proteins aims to provide new options for patients with limited treatment choices.